The respiratory tract infection therapy developer, which counts Novartis and PureTech Health as investors, has closed its IPO at $97.8m.
Restorbio, a US-based developer of treatments for ageing-related diseases, closed an initial public offering that scored an exit for pharmaceutical firm Novartis at approximately $97.8m yesterday.
The IPO initially consisted of almost 5.7 million shares being issued on the Nasdaq Global Select Market on Friday priced at $15.00 each, the middle of the offering’s $14 to $16 range, raising just over $85m.
Joint book-running managers BofA Merrill Lynch, Leerink Partners and Evercore ISI have joined co-manager Wedbush PacGrow to…
